Serum Institute of India, the world’s largest vaccine manufacturer, has sought permission from the Drugs Controller General of India (DCGI) to conduct a small home trial of the Novavax Corona Virus vaccine. This will be the second Kovid-19 vaccine to be manufactured locally by the company. The Drug Controller General of India VG Somani and the committee of subject experts of the Central Drug Standards Control Organization are examining the application process. Actually, the Serum Institute has tied up with American pharmaceutical company Novavax Inc. for the production and distribution of this vaccine. According to the agreement, the Serum Institute will produce two billion doses of this vaccine every year.
In the trial conducted in Britain, this vaccine has been found to be 89.3 percent effective. Not only this, it has also been found to be effective against the Corona strain (UK corona variant) found in Britain. But the results of the Phase-3 clinical trial are somewhat disappointing compared to other results suggesting that this vaccine is not effective against the Corona strain encountered in South Africa. Found in South Africa, this corona strain (South Africa)
Novavax’s vaccine is a vaccine based on the protein unit platform. Virus fragments have been used in this. This vaccine will train the body to protect against the corona virus and not strengthen immunity. This vaccine has been described as suitable for India, as it does not require a much lower temperature than many other vaccines for its storage.
%20to%20conduct%20a%20small%20home%20trial%20of%20the%20Novavax%20Corona%20Virus%20vaccine.%20This%20will%20be%20the%20second%20Kovid-19%20vaccine%20to%20be%20manufactured%20locally%20by%20the%20company.){kind=link}